Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027
Global liquid biopsy market was valued at USD 2,728.57 million in 2021, and during the forecast period, it is expected to expand at a CAGR of 13.77%. An alternate way of detecting and diagnosing cancer is liquid biopsy. The primary reason propelling the growth of the liquid biopsy market is the rising incidence of cancer worldwide. Liquid biopsies aid in the early detection of cancer while traditional biopsy techniques do not allow the detection of cancer in the aged population.
Due to factors such as the rising prevalence of cancer, increased funding for research to find new biomarkers, and increased emphasis on the use of liquid biopsy, the market is anticipated to experience rapid expansion.
The rise of the industry is partly a result of substantial investments made by biotechnology firms in the research and development of liquid biopsies. A further factor driving the growth of the liquid biopsy market in the years to come is the increasing use of liquid biopsy among prominent end users.
Rising Incidence of Cancer
Several factors, including tobacco use, alcohol use, poor food, physical inactivity, and air pollution, are contributing to the rise in cancer cases in the modern world. The global incidence of cancer is rising, making it the second biggest cause of death. Breast cancer is now the most prevalent type of cancer diagnosed worldwide due to the increased prevalence of the disease among females.
Growing adoption of Liquid Biopsy among major end users
As prospective screening, diagnostic, prognostic, and predictive tests in cancer, liquid biopsies have gained a lot of interest. Clinical oncology has undergone a significant revolution owing to liquid biopsy, which makes it easier to sample tumors, provide continuous monitoring through repeated sampling, enable the creation of specific treatment plans, and test for therapeutic resistance. Since most cancers are in contact with blood, liquid biopsy mostly includes blood collection, though mucosa, pleural effusions, urine, and cerebrospinal fluid (CSF) are also examined during the procedure. As a result, Liquid Biopsy offers improved diagnosis sensitivity and simplicity of recurring sampling throughout therapy in a far more practical and non-invasive manner.
Increased Awareness Regarding Cancer
Today's population is more aware of the signs and symptoms of cancer, and they try to have their illness diagnosed when it is still in its early stages. As a result of early cancer detection, tumor progression monitoring, and clinical prognosis assessment capabilities, liquid biopsy technology is experiencing market expansion.
Market Segmentation
The Global Liquid Biopsy Market is segmented based on Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, and Region. Based on Offering, the market can be split into Testing Service, Kits, Platform, Other Consumables. Based on Technology, the market can be divided into Next Generation Sequencing, Polymerase Chain Reactions, Others. Based on Workflow, the market is divided into Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management. Based on Sample, the market is divided into Blood, Urine, Saliva, Others.
Based on Circulating Biomarker, the market is divided into Circulating Tumor Cells (CTCs), Cell Free RNAs, Exosomes & Extracellular Vesicles, Others. In terms of Application, the market can be categorized into Oncological v/s non-Oncological. Based on End User, the market is split into Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes.
Company Profiles
F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., LungLife AI, Inc., Illumina, Inc., QIAGEN NV, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., Guardant Health Inc., Natera, Inc., Sysmex Corporation, Abcodia Ltd., Dxcover Limited are among some of the major market players in the Global Liquid Biopsy Market.
Report Scope:
In this report, Global Liquid Biopsy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Liquid Biopsy market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Due to factors such as the rising prevalence of cancer, increased funding for research to find new biomarkers, and increased emphasis on the use of liquid biopsy, the market is anticipated to experience rapid expansion.
The rise of the industry is partly a result of substantial investments made by biotechnology firms in the research and development of liquid biopsies. A further factor driving the growth of the liquid biopsy market in the years to come is the increasing use of liquid biopsy among prominent end users.
Rising Incidence of Cancer
Several factors, including tobacco use, alcohol use, poor food, physical inactivity, and air pollution, are contributing to the rise in cancer cases in the modern world. The global incidence of cancer is rising, making it the second biggest cause of death. Breast cancer is now the most prevalent type of cancer diagnosed worldwide due to the increased prevalence of the disease among females.
Growing adoption of Liquid Biopsy among major end users
As prospective screening, diagnostic, prognostic, and predictive tests in cancer, liquid biopsies have gained a lot of interest. Clinical oncology has undergone a significant revolution owing to liquid biopsy, which makes it easier to sample tumors, provide continuous monitoring through repeated sampling, enable the creation of specific treatment plans, and test for therapeutic resistance. Since most cancers are in contact with blood, liquid biopsy mostly includes blood collection, though mucosa, pleural effusions, urine, and cerebrospinal fluid (CSF) are also examined during the procedure. As a result, Liquid Biopsy offers improved diagnosis sensitivity and simplicity of recurring sampling throughout therapy in a far more practical and non-invasive manner.
Increased Awareness Regarding Cancer
Today's population is more aware of the signs and symptoms of cancer, and they try to have their illness diagnosed when it is still in its early stages. As a result of early cancer detection, tumor progression monitoring, and clinical prognosis assessment capabilities, liquid biopsy technology is experiencing market expansion.
Market Segmentation
The Global Liquid Biopsy Market is segmented based on Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, and Region. Based on Offering, the market can be split into Testing Service, Kits, Platform, Other Consumables. Based on Technology, the market can be divided into Next Generation Sequencing, Polymerase Chain Reactions, Others. Based on Workflow, the market is divided into Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management. Based on Sample, the market is divided into Blood, Urine, Saliva, Others.
Based on Circulating Biomarker, the market is divided into Circulating Tumor Cells (CTCs), Cell Free RNAs, Exosomes & Extracellular Vesicles, Others. In terms of Application, the market can be categorized into Oncological v/s non-Oncological. Based on End User, the market is split into Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes.
Company Profiles
F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., LungLife AI, Inc., Illumina, Inc., QIAGEN NV, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., Guardant Health Inc., Natera, Inc., Sysmex Corporation, Abcodia Ltd., Dxcover Limited are among some of the major market players in the Global Liquid Biopsy Market.
Report Scope:
In this report, Global Liquid Biopsy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Liquid Biopsy Market, By Offering:
- Testing Service
- Kits
- Platform
- Other consumables
- Liquid Biopsy Market, By Technology:
- Polymerase Chain Reaction
- Next Generation Sequencing
- Others
- Liquid Biopsy Market, By Workflow:
- Sample Preparation
- Library Preparation
- Sequencing
- Data Analysis & Management
- Liquid Biopsy Market, By Sample:
- Blood
- Urine
- Saliva
- Others
- Liquid Biopsy Market, By Circulating Biomarkers:
- Circulating Tumor Cells (CTCs)
- Cell-free Nucleic Acids
- Exosomes & Extracellular Vesicles
- Others
- Liquid Biopsy Market, By Application:
- Oncological
- Non- Oncological
- Liquid Biopsy Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Netherlands
- Belgium
- Denmark
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- New Zealand
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- Turkey
- Egypt
- Saudi Arabia
- South Africa
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Liquid Biopsy market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL LIQUID BIOPSY MARKET
5. VOICE OF CUSTOMER
5.1. Cancer Prevalence, By Gender
5.2. Cancer Prevalence, By Age Group
5.3. Cancer Prevalence, By Region
5.4. Common Methods Used for Cancer Detection
5.5. Benefits of Using Liquid Biopsy
5.6. Barriers to Adoption of Liquid Biopsy
6. CLINICAL TRIAL ANALYSIS
7. PATENT ANALYSIS
8. GLOBAL LIQUID BIOPSY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
8.2.4. By Sample (Blood, Urine, Saliva, Others)
8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
8.2.6. By Application (Oncological v/s non-Oncological)
8.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
8.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
8.2.8. By Company (2021)
8.2.9. By Region
8.3. Market Map
9. NORTH AMERICA LIQUID BIOPSY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
9.2.4. By Sample (Blood, Urine, Saliva, Others)
9.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
9.2.6. By Application (Oncological v/s non-Oncological)
9.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
9.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
9.2.8. By Country
9.3. North America: Country Analysis
9.3.1. United States Liquid Biopsy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Offering
9.3.1.2.2. By Technology
9.3.1.2.3. By Workflow
9.3.1.2.4. By Sample
9.3.1.2.5. By Circulating Biomarker
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. Canada Liquid Biopsy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Offering
9.3.2.2.2. By Technology
9.3.2.2.3. By Workflow
9.3.2.2.4. By Sample
9.3.2.2.5. By Circulating Biomarker
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. Mexico Liquid Biopsy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Offering
9.3.3.2.2. By Technology
9.3.3.2.3. By Workflow
9.3.3.2.4. By Sample
9.3.3.2.5. By Circulating Biomarker
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. EUROPE LIQUID BIOPSY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
10.2.4. By Sample (Blood, Urine, Saliva, Others)
10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
10.2.6. By Application (Oncological v/s non-Oncological)
10.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
10.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
10.2.7. By End User (Academic & Research Institutes, Clinical Laboratories, , Pharmaceutical & Biotechnology Companies)
10.2.8. By Country
10.3. Europe: Country Analysis
10.3.1. Germany Liquid Biopsy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Offering
10.3.1.2.2. By Technology
10.3.1.2.3. By Workflow
10.3.1.2.4. By Sample
10.3.1.2.5. By Circulating Biomarker
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. France Liquid Biopsy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Offering
10.3.2.2.2. By Technology
10.3.2.2.3. By Workflow
10.3.2.2.4. By Sample
10.3.2.2.5. By Circulating Biomarker
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. United Kingdom Liquid Biopsy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Offering
10.3.3.2.2. By Technology
10.3.3.2.3. By Workflow
10.3.3.2.4. By Sample
10.3.3.2.5. By Circulating Biomarker
10.3.3.2.6. By Application
10.3.3.2.7. By End User
10.3.4. Italy Liquid Biopsy Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Offering
10.3.4.2.2. By Technology
10.3.4.2.3. By Workflow
10.3.4.2.4. By Sample
10.3.4.2.5. By Circulating Biomarker
10.3.4.2.6. By Application
10.3.4.2.7. By End User
10.3.5. Spain Liquid Biopsy Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Offering
10.3.5.2.2. By Technology
10.3.5.2.3. By Workflow
10.3.5.2.4. By Sample
10.3.5.2.5. By Circulating Biomarker
10.3.5.2.6. By Application
10.3.5.2.7. By End User
10.3.6. Netherlands Liquid Biopsy Market Outlook
10.3.6.1. Market Size & Forecast
10.3.6.1.1. By Value
10.3.6.2. Market Share & Forecast
10.3.6.2.1. By Offering
10.3.6.2.2. By Technology
10.3.6.2.3. By Workflow
10.3.6.2.4. By Sample
10.3.6.2.5. By Circulating Biomarker
10.3.6.2.6. By Application
10.3.6.2.7. By End User
10.3.7. Belgium Liquid Biopsy Market Outlook
10.3.7.1. Market Size & Forecast
10.3.7.1.1. By Value
10.3.7.2. Market Share & Forecast
10.3.7.2.1. By Offering
10.3.7.2.2. By Technology
10.3.7.2.3. By Workflow
10.3.7.2.4. By Sample
10.3.7.2.5. By Circulating Biomarker
10.3.7.2.6. By Application
10.3.7.2.7. By End User
10.3.8. Denmark Liquid Biopsy Market Outlook
10.3.8.1. Market Size & Forecast
10.3.8.1.1. By Value
10.3.8.2. Market Share & Forecast
10.3.8.2.1. By Offering
10.3.8.2.2. By Technology
10.3.8.2.3. By Workflow
10.3.8.2.4. By Sample
10.3.8.2.5. By Circulating Biomarker
10.3.8.2.6. By Application
10.3.8.2.7. By End User
11. ASIA-PACIFIC LIQUID BIOPSY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
11.2.4. By Sample (Blood, Urine, Saliva, Others)
11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
11.2.6. By Application (Oncological v/s non-Oncological)
11.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
11.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
11.2.8. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Liquid Biopsy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Offering
11.3.1.2.2. By Technology
11.3.1.2.3. By Workflow
11.3.1.2.4. By Sample
11.3.1.2.5. By Circulating Biomarker
11.3.1.2.6. By Application
11.3.1.2.7. By End User
11.3.2. India Liquid Biopsy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Offering
11.3.2.2.2. By Technology
11.3.2.2.3. By Workflow
11.3.2.2.4. By Sample
11.3.2.2.5. By Circulating Biomarker
11.3.2.2.6. By Application
11.3.2.2.7. By End User
11.3.3. Japan Liquid Biopsy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Offering
11.3.3.2.2. By Technology
11.3.3.2.3. By Workflow
11.3.3.2.4. By Sample
11.3.3.2.5. By Circulating Biomarker
11.3.3.2.6. By Application
11.3.3.2.7. By End User
11.3.4. South Korea Liquid Biopsy Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Offering
11.3.4.2.2. By Technology
11.3.4.2.3. By Workflow
11.3.4.2.4. By Sample
11.3.4.2.5. By Circulating Biomarker
11.3.4.2.6. By Application
11.3.4.2.7. By End User
11.3.5. Australia Liquid Biopsy Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Offering
11.3.5.2.2. By Technology
11.3.5.2.3. By Workflow
11.3.5.2.4. By Sample
11.3.5.2.5. By Circulating Biomarker
11.3.5.2.6. By Application
11.3.5.2.7. By End User
11.3.6. New Zealand Liquid Biopsy Market Outlook
11.3.6.1. Market Size & Forecast
11.3.6.1.1. By Value
11.3.6.2. Market Share & Forecast
11.3.6.2.1. By Offering
11.3.6.2.2. By Technology
11.3.6.2.3. By Workflow
11.3.6.2.4. By Sample
11.3.6.2.5. By Circulating Biomarker
11.3.6.2.6. By Application
11.3.6.2.7. By End User
12. SOUTH AMERICA LIQUID BIOPSY MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
12.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
12.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
12.2.4. By Sample (Blood, Urine, Saliva, Others)
12.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
12.2.6. By Application (Oncological v/s non-Oncological)
12.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)
12.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
12.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)
12.2.8. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Liquid Biopsy Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Offering
12.3.1.2.2. By Technology
12.3.1.2.3. By Workflow
12.3.1.2.4. By Sample
12.3.1.2.5. By Circulating Biomarker
12.3.1.2.6. By Application
12.3.1.2.7. By End User
12.3.2. Argentina Liquid Biopsy Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Offering
12.3.2.2.2. By Technology
12.3.2.2.3. By Workflow
12.3.2.2.4. By Sample
12.3.2.2.5. By Circulating Biomarker
12.3.2.2.6. By Application
12.3.2.2.7. By End User
12.3.3. Colombia Liquid Biopsy Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Offering
12.3.3.2.2. By Technology
12.3.3.2.3. By Workflow
12.3.3.2.4. By Sample
12.3.3.2.5. By Circulating Biomarker
12.3.3.2.6. By Application
12.3.3.2.7. By End User
13. MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET OUTLOOK
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
13.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
13.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
13.2.4. By Sample (Blood, Urine, Saliva, Others)
13.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Circulating Cell Free RNAs, Exosomes & Extracellular Vesicles, Others)
13.2.6. By Application (Oncological v/s non-Oncological)
13.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)
13.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
13.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)
13.2.8. By Country
13.3. MEA: Country Analysis
13.3.1. Turkey Liquid Biopsy Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Offering
13.3.1.2.2. By Technology
13.3.1.2.3. By Workflow
13.3.1.2.4. By Sample
13.3.1.2.5. By Circulating Biomarker
13.3.1.2.6. By Application
13.3.1.2.7. By End User
13.3.2. Egypt Liquid Biopsy Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Offering
13.3.2.2.2. By Technology
13.3.2.2.3. By Workflow
13.3.2.2.4. By Sample
13.3.2.2.5. By Circulating Biomarker
13.3.2.2.6. By Application
13.3.2.2.7. By End User
13.3.3. Saudi Arabia Liquid Biopsy Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Offering
13.3.3.2.2. By Technology
13.3.3.2.3. By Workflow
13.3.3.2.4. By Sample
13.3.3.2.5. By Circulating Biomarker
13.3.3.2.6. By Application
13.3.3.2.7. By End User
13.3.4. South Africa Liquid Biopsy Market Outlook
13.3.4.1. Market Size & Forecast
13.3.4.1.1. By Value
13.3.4.2. Market Share & Forecast
13.3.4.2.1. By Offering
13.3.4.2.2. By Technology
13.3.4.2.3. By Workflow
13.3.4.2.4. By Sample
13.3.4.2.5. By Circulating Biomarker
13.3.4.2.6. By Application
13.3.4.2.7. By End User
13.3.5. UAE Liquid Biopsy Market Outlook
13.3.5.1. Market Size & Forecast
13.3.5.1.1. By Value
13.3.5.2. Market Share & Forecast
13.3.5.2.1. By Offering
13.3.5.2.2. By Technology
13.3.5.2.3. By Workflow
13.3.5.2.4. By Sample
13.3.5.2.5. By Circulating Biomarker
13.3.5.2.6. By Application
13.3.5.2.7. By End User
14. MARKET DYNAMICS
14.1. Drivers
14.2. Challenges
15. MARKET TRENDS & DEVELOPMENTS
16. COMPETITIVE LANDSCAPE (INCLUSIVE OF SWOT ANALYSIS)
16.1. F. Hoffmann-La Roche AG
16.2. Thermo Fisher Scientific, Inc.
16.3. PerkinElmer Inc.
16.4. LungLife AI, Inc.
16.5. Illumina, Inc.
16.6. QIAGEN NV
16.7. NeoGenomics Laboratories, Inc.
16.8. Myriad Genetics, Inc.
16.9. Biocept, Inc.
16.10. Bio-Rad Laboratories, Inc.
16.11. Guardant Health Inc.
16.12. Natera, Inc.
16.13. Sysmex Corporation
16.14. Abcodia Ltd.
16.15. Dxcover Limited
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL LIQUID BIOPSY MARKET
5. VOICE OF CUSTOMER
5.1. Cancer Prevalence, By Gender
5.2. Cancer Prevalence, By Age Group
5.3. Cancer Prevalence, By Region
5.4. Common Methods Used for Cancer Detection
5.5. Benefits of Using Liquid Biopsy
5.6. Barriers to Adoption of Liquid Biopsy
6. CLINICAL TRIAL ANALYSIS
7. PATENT ANALYSIS
8. GLOBAL LIQUID BIOPSY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
8.2.4. By Sample (Blood, Urine, Saliva, Others)
8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
8.2.6. By Application (Oncological v/s non-Oncological)
8.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
8.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
8.2.8. By Company (2021)
8.2.9. By Region
8.3. Market Map
9. NORTH AMERICA LIQUID BIOPSY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
9.2.4. By Sample (Blood, Urine, Saliva, Others)
9.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
9.2.6. By Application (Oncological v/s non-Oncological)
9.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
9.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
9.2.8. By Country
9.3. North America: Country Analysis
9.3.1. United States Liquid Biopsy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Offering
9.3.1.2.2. By Technology
9.3.1.2.3. By Workflow
9.3.1.2.4. By Sample
9.3.1.2.5. By Circulating Biomarker
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. Canada Liquid Biopsy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Offering
9.3.2.2.2. By Technology
9.3.2.2.3. By Workflow
9.3.2.2.4. By Sample
9.3.2.2.5. By Circulating Biomarker
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. Mexico Liquid Biopsy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Offering
9.3.3.2.2. By Technology
9.3.3.2.3. By Workflow
9.3.3.2.4. By Sample
9.3.3.2.5. By Circulating Biomarker
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. EUROPE LIQUID BIOPSY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
10.2.4. By Sample (Blood, Urine, Saliva, Others)
10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
10.2.6. By Application (Oncological v/s non-Oncological)
10.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
10.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
10.2.7. By End User (Academic & Research Institutes, Clinical Laboratories, , Pharmaceutical & Biotechnology Companies)
10.2.8. By Country
10.3. Europe: Country Analysis
10.3.1. Germany Liquid Biopsy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Offering
10.3.1.2.2. By Technology
10.3.1.2.3. By Workflow
10.3.1.2.4. By Sample
10.3.1.2.5. By Circulating Biomarker
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. France Liquid Biopsy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Offering
10.3.2.2.2. By Technology
10.3.2.2.3. By Workflow
10.3.2.2.4. By Sample
10.3.2.2.5. By Circulating Biomarker
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. United Kingdom Liquid Biopsy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Offering
10.3.3.2.2. By Technology
10.3.3.2.3. By Workflow
10.3.3.2.4. By Sample
10.3.3.2.5. By Circulating Biomarker
10.3.3.2.6. By Application
10.3.3.2.7. By End User
10.3.4. Italy Liquid Biopsy Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Offering
10.3.4.2.2. By Technology
10.3.4.2.3. By Workflow
10.3.4.2.4. By Sample
10.3.4.2.5. By Circulating Biomarker
10.3.4.2.6. By Application
10.3.4.2.7. By End User
10.3.5. Spain Liquid Biopsy Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Offering
10.3.5.2.2. By Technology
10.3.5.2.3. By Workflow
10.3.5.2.4. By Sample
10.3.5.2.5. By Circulating Biomarker
10.3.5.2.6. By Application
10.3.5.2.7. By End User
10.3.6. Netherlands Liquid Biopsy Market Outlook
10.3.6.1. Market Size & Forecast
10.3.6.1.1. By Value
10.3.6.2. Market Share & Forecast
10.3.6.2.1. By Offering
10.3.6.2.2. By Technology
10.3.6.2.3. By Workflow
10.3.6.2.4. By Sample
10.3.6.2.5. By Circulating Biomarker
10.3.6.2.6. By Application
10.3.6.2.7. By End User
10.3.7. Belgium Liquid Biopsy Market Outlook
10.3.7.1. Market Size & Forecast
10.3.7.1.1. By Value
10.3.7.2. Market Share & Forecast
10.3.7.2.1. By Offering
10.3.7.2.2. By Technology
10.3.7.2.3. By Workflow
10.3.7.2.4. By Sample
10.3.7.2.5. By Circulating Biomarker
10.3.7.2.6. By Application
10.3.7.2.7. By End User
10.3.8. Denmark Liquid Biopsy Market Outlook
10.3.8.1. Market Size & Forecast
10.3.8.1.1. By Value
10.3.8.2. Market Share & Forecast
10.3.8.2.1. By Offering
10.3.8.2.2. By Technology
10.3.8.2.3. By Workflow
10.3.8.2.4. By Sample
10.3.8.2.5. By Circulating Biomarker
10.3.8.2.6. By Application
10.3.8.2.7. By End User
11. ASIA-PACIFIC LIQUID BIOPSY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
11.2.4. By Sample (Blood, Urine, Saliva, Others)
11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
11.2.6. By Application (Oncological v/s non-Oncological)
11.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
11.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
11.2.8. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Liquid Biopsy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Offering
11.3.1.2.2. By Technology
11.3.1.2.3. By Workflow
11.3.1.2.4. By Sample
11.3.1.2.5. By Circulating Biomarker
11.3.1.2.6. By Application
11.3.1.2.7. By End User
11.3.2. India Liquid Biopsy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Offering
11.3.2.2.2. By Technology
11.3.2.2.3. By Workflow
11.3.2.2.4. By Sample
11.3.2.2.5. By Circulating Biomarker
11.3.2.2.6. By Application
11.3.2.2.7. By End User
11.3.3. Japan Liquid Biopsy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Offering
11.3.3.2.2. By Technology
11.3.3.2.3. By Workflow
11.3.3.2.4. By Sample
11.3.3.2.5. By Circulating Biomarker
11.3.3.2.6. By Application
11.3.3.2.7. By End User
11.3.4. South Korea Liquid Biopsy Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Offering
11.3.4.2.2. By Technology
11.3.4.2.3. By Workflow
11.3.4.2.4. By Sample
11.3.4.2.5. By Circulating Biomarker
11.3.4.2.6. By Application
11.3.4.2.7. By End User
11.3.5. Australia Liquid Biopsy Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Offering
11.3.5.2.2. By Technology
11.3.5.2.3. By Workflow
11.3.5.2.4. By Sample
11.3.5.2.5. By Circulating Biomarker
11.3.5.2.6. By Application
11.3.5.2.7. By End User
11.3.6. New Zealand Liquid Biopsy Market Outlook
11.3.6.1. Market Size & Forecast
11.3.6.1.1. By Value
11.3.6.2. Market Share & Forecast
11.3.6.2.1. By Offering
11.3.6.2.2. By Technology
11.3.6.2.3. By Workflow
11.3.6.2.4. By Sample
11.3.6.2.5. By Circulating Biomarker
11.3.6.2.6. By Application
11.3.6.2.7. By End User
12. SOUTH AMERICA LIQUID BIOPSY MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
12.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
12.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
12.2.4. By Sample (Blood, Urine, Saliva, Others)
12.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
12.2.6. By Application (Oncological v/s non-Oncological)
12.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)
12.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
12.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)
12.2.8. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Liquid Biopsy Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Offering
12.3.1.2.2. By Technology
12.3.1.2.3. By Workflow
12.3.1.2.4. By Sample
12.3.1.2.5. By Circulating Biomarker
12.3.1.2.6. By Application
12.3.1.2.7. By End User
12.3.2. Argentina Liquid Biopsy Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Offering
12.3.2.2.2. By Technology
12.3.2.2.3. By Workflow
12.3.2.2.4. By Sample
12.3.2.2.5. By Circulating Biomarker
12.3.2.2.6. By Application
12.3.2.2.7. By End User
12.3.3. Colombia Liquid Biopsy Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Offering
12.3.3.2.2. By Technology
12.3.3.2.3. By Workflow
12.3.3.2.4. By Sample
12.3.3.2.5. By Circulating Biomarker
12.3.3.2.6. By Application
12.3.3.2.7. By End User
13. MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET OUTLOOK
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
13.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
13.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
13.2.4. By Sample (Blood, Urine, Saliva, Others)
13.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Circulating Cell Free RNAs, Exosomes & Extracellular Vesicles, Others)
13.2.6. By Application (Oncological v/s non-Oncological)
13.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)
13.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
13.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)
13.2.8. By Country
13.3. MEA: Country Analysis
13.3.1. Turkey Liquid Biopsy Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Offering
13.3.1.2.2. By Technology
13.3.1.2.3. By Workflow
13.3.1.2.4. By Sample
13.3.1.2.5. By Circulating Biomarker
13.3.1.2.6. By Application
13.3.1.2.7. By End User
13.3.2. Egypt Liquid Biopsy Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Offering
13.3.2.2.2. By Technology
13.3.2.2.3. By Workflow
13.3.2.2.4. By Sample
13.3.2.2.5. By Circulating Biomarker
13.3.2.2.6. By Application
13.3.2.2.7. By End User
13.3.3. Saudi Arabia Liquid Biopsy Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Offering
13.3.3.2.2. By Technology
13.3.3.2.3. By Workflow
13.3.3.2.4. By Sample
13.3.3.2.5. By Circulating Biomarker
13.3.3.2.6. By Application
13.3.3.2.7. By End User
13.3.4. South Africa Liquid Biopsy Market Outlook
13.3.4.1. Market Size & Forecast
13.3.4.1.1. By Value
13.3.4.2. Market Share & Forecast
13.3.4.2.1. By Offering
13.3.4.2.2. By Technology
13.3.4.2.3. By Workflow
13.3.4.2.4. By Sample
13.3.4.2.5. By Circulating Biomarker
13.3.4.2.6. By Application
13.3.4.2.7. By End User
13.3.5. UAE Liquid Biopsy Market Outlook
13.3.5.1. Market Size & Forecast
13.3.5.1.1. By Value
13.3.5.2. Market Share & Forecast
13.3.5.2.1. By Offering
13.3.5.2.2. By Technology
13.3.5.2.3. By Workflow
13.3.5.2.4. By Sample
13.3.5.2.5. By Circulating Biomarker
13.3.5.2.6. By Application
13.3.5.2.7. By End User
14. MARKET DYNAMICS
14.1. Drivers
14.2. Challenges
15. MARKET TRENDS & DEVELOPMENTS
16. COMPETITIVE LANDSCAPE (INCLUSIVE OF SWOT ANALYSIS)
16.1. F. Hoffmann-La Roche AG
16.2. Thermo Fisher Scientific, Inc.
16.3. PerkinElmer Inc.
16.4. LungLife AI, Inc.
16.5. Illumina, Inc.
16.6. QIAGEN NV
16.7. NeoGenomics Laboratories, Inc.
16.8. Myriad Genetics, Inc.
16.9. Biocept, Inc.
16.10. Bio-Rad Laboratories, Inc.
16.11. Guardant Health Inc.
16.12. Natera, Inc.
16.13. Sysmex Corporation
16.14. Abcodia Ltd.
16.15. Dxcover Limited
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
LIST OF FIGURES
Figure 1: Global Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 2: Global Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 3: Global Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 4: Global Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 5: Global Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 6: Global Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 7: Global Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 8: Global Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 9: Global Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 10: Global Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 11: Global Liquid Biopsy Market Share, By Region, By Value, 2017-2027F
Figure 12: Global Liquid Biopsy Market Share, By Company, By Value, 2017-2027F
Figure 13: Global Liquid Biopsy Market Map, By Offering, Market Size (USD Million) & Growth Rate (%), 2021
Figure 14: Global Liquid Biopsy Market Map, By Technology, Market Size (USD Million) & Growth Rate (%), 2021
Figure 15: Global Liquid Biopsy Market Map, By Workflow, Market Size (USD Million) & Growth Rate (%), 2021
Figure 16: Global Liquid Biopsy Market Map, By Sample, Market Size (USD Million) & Growth Rate (%), 2021
Figure 17: Global Liquid Biopsy Market Map, By Circulating Biomarker, Market Size (USD Million) & Growth Rate (%), 2021
Figure 18: Global Liquid Biopsy Market Map, By Application, Market Size (USD Million) & Growth Rate (%), 2021
Figure 19: Global Liquid Biopsy Market Map, By End User, Market Size (USD Million) & Growth Rate (%), 2021
Figure 20: Global Liquid Biopsy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021
Figure 21: North America Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 22: North America Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 23: North America Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 24: North America Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 25: North America Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 26: North America Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 27: North America Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 28: North America Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 29: North America Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 30: North America Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 31: North America Liquid Biopsy Market Share, By Country, By Value, 2017-2027F
Figure 32: United States Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 33: United States Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 34: United States Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 35: United States Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 36: United States Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 37: United States Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 38: United States Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 39: United States Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 40: United States Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 41: United States Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 42: Canada Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 43: Canada Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 44: Canada Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 45: Canada Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 46: Canada Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 47: Canada Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 48: Canada Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 49: Canada Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 50: Canada Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 51: Canada Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 52: Mexico Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 53: Mexico Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 54: Mexico Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 55: Mexico Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 56: Mexico Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 57: Mexico Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 58: Mexico Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 59: Mexico Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 60: Mexico Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 61: Mexico Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 62: Europe Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 63: Europe Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 64: Europe Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 65: Europe Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 66: Europe Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 67: Europe Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 68: Europe Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 69: Europe Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 70: Europe Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 71: Europe Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 72: Europe Liquid Biopsy Market Share, By Country, By Value, 2017-2027F
Figure 73: Germany Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 74: Germany Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 75: Germany Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 76: Germany Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 77: Germany Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 78: Germany Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 79: Germany Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 80: Germany Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 81: Germany Liquid Biopsy Market Share, By Appl
Figure 1: Global Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 2: Global Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 3: Global Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 4: Global Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 5: Global Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 6: Global Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 7: Global Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 8: Global Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 9: Global Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 10: Global Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 11: Global Liquid Biopsy Market Share, By Region, By Value, 2017-2027F
Figure 12: Global Liquid Biopsy Market Share, By Company, By Value, 2017-2027F
Figure 13: Global Liquid Biopsy Market Map, By Offering, Market Size (USD Million) & Growth Rate (%), 2021
Figure 14: Global Liquid Biopsy Market Map, By Technology, Market Size (USD Million) & Growth Rate (%), 2021
Figure 15: Global Liquid Biopsy Market Map, By Workflow, Market Size (USD Million) & Growth Rate (%), 2021
Figure 16: Global Liquid Biopsy Market Map, By Sample, Market Size (USD Million) & Growth Rate (%), 2021
Figure 17: Global Liquid Biopsy Market Map, By Circulating Biomarker, Market Size (USD Million) & Growth Rate (%), 2021
Figure 18: Global Liquid Biopsy Market Map, By Application, Market Size (USD Million) & Growth Rate (%), 2021
Figure 19: Global Liquid Biopsy Market Map, By End User, Market Size (USD Million) & Growth Rate (%), 2021
Figure 20: Global Liquid Biopsy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021
Figure 21: North America Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 22: North America Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 23: North America Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 24: North America Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 25: North America Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 26: North America Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 27: North America Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 28: North America Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 29: North America Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 30: North America Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 31: North America Liquid Biopsy Market Share, By Country, By Value, 2017-2027F
Figure 32: United States Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 33: United States Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 34: United States Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 35: United States Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 36: United States Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 37: United States Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 38: United States Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 39: United States Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 40: United States Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 41: United States Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 42: Canada Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 43: Canada Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 44: Canada Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 45: Canada Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 46: Canada Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 47: Canada Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 48: Canada Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 49: Canada Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 50: Canada Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 51: Canada Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 52: Mexico Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 53: Mexico Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 54: Mexico Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 55: Mexico Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 56: Mexico Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 57: Mexico Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 58: Mexico Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 59: Mexico Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 60: Mexico Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 61: Mexico Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 62: Europe Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 63: Europe Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 64: Europe Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 65: Europe Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 66: Europe Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 67: Europe Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 68: Europe Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 69: Europe Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 70: Europe Liquid Biopsy Market Share, By Application, By Non-Oncological, By Value, 2017-2027F
Figure 71: Europe Liquid Biopsy Market Share, By End User, By Value, 2017-2027F
Figure 72: Europe Liquid Biopsy Market Share, By Country, By Value, 2017-2027F
Figure 73: Germany Liquid Biopsy Market Size, By Value (USD Million), 2017-2027F
Figure 74: Germany Liquid Biopsy Market Share, By Offering, By Value, 2017-2027F
Figure 75: Germany Liquid Biopsy Market Share, By Technology, By Value, 2017-2027F
Figure 76: Germany Liquid Biopsy Market Share, By Workflow, By Value, 2017-2027F
Figure 77: Germany Liquid Biopsy Market Share, By Sample, By Value, 2017-2027F
Figure 78: Germany Liquid Biopsy Market Share, By Circulating Biomarker, By Value, 2017-2027F
Figure 79: Germany Liquid Biopsy Market Share, By Application, By Value, 2017-2027F
Figure 80: Germany Liquid Biopsy Market Share, By Application, By Oncological, By Value, 2017-2027F
Figure 81: Germany Liquid Biopsy Market Share, By Appl
